Eli Lilly to Acquire Three Vaccine Developers for Nearly $4 Billion

Eli Lilly has announced plans to acquire three vaccine developers in deals totaling nearly $4 billion. This strategic move aims to bolster the pharmaceutical giant's presence in the infectious disease sector.

26 May, 10:58 — 26 May, 16:26

Post Share

Why this matters

This acquisition marks a significant expansion for Eli Lilly into the vaccine market, potentially diversifying its product pipeline and revenue streams beyond its traditional focus areas. It could also signal a broader trend of pharmaceutical giants investing more heavily in vaccine development.

Key entitiesEli Lilly

The Story

What 7 sources agree on, dispute, and miss

What sources agree on

Eli Lilly is acquiring three vaccine developers
The total value of the acquisitions is up to $4 billion

Key claims2 agreed · 1 unverified

✓

Eli Lilly is acquiring three vaccine developers

agreed·Yahooseeking-alpha

✓

The deals are worth up to $4 billion

agreed·seeking-alphaYahoo

The acquisition price is $3.8 billion

unverified·Yahoo

Coverage gaps

The specific acquisition price of $3.8 billion

ReportedYahoo

Missingseeking-alpha

The Story

Analyzing sources…

Source Diversity

High (67/100)

7 sources33/33

Spectrum spread— 4/5 buckets covered25/33

Far L1

Far Left (1)

NYT

Left2

Left (2)

cnbcYahoo

Center2

Center (2)

Reutersbloomberg

Right2

Right (2)

wsjseeking-alpha

Far R

Geographic diversity— 2 regions9/34

US6Intl1

Sources

Showing 7 of 7 sources

ReutersVery High2d ago

Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push - Reuters

Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push Reuters

Read full article →

NYTMostly Factual2d ago

Eli Lilly to Buy 3 Vaccine Developers

The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr virus and other pathogens.

By Rebecca Robbins

Read full article →

bloombergHigh2d ago